换一批美国肝病学会《瑞美替罗治疗代谢功能障碍相关脂肪性肝病实践指南(2024年10月更新版)》摘译
Key points in Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance
摘要2024年3月瑞美替罗已获得美国食品和药品监督管理局的加速批准，用于治疗伴有肝纤维化2～3期的代谢相关脂肪性肝炎。本文摘译自美国肝病学会(AASLD)颁布的《瑞美替罗治疗代谢相关脂肪性肝病实践指南(2024年更新版)》，旨在为临床医师提供用药指导。
更多相关知识
abstractsResmetirom received accelerated approval from the United States Food and Drug Administration (FDA) in March 2024 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (stages F2 to F3 fibrosis). This article is excerpted from the Resmetirom therapy for metabolic dysfunction- associated steatotic liver disease: October 2024 updates to AASLD practice guidance. The purpose of this article is to provide medication guidance to clinicians.
More相关知识
栏目名称
DOI
10.3760/cma.j.cn311367-20250313-00106
发布时间
2025-05-15（万方平台首次上网日期，不代表论文的发表时间）
- 浏览7
- 被引0
- 下载3
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
